Catinazzo Thomas sold $329K of RLAY
Catinazzo Thomas (Chief Financial Officer) sold 17,717 shares of Relay Therapeutics, Inc. (RLAY) at an average of $18.59 ($18.58–$19.26, $0.33M total) across 2 trades on 2026-10-06 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale provides fresh data on insider holdings, potentially influencing short‑term sentiment.
Market read
First‑report insider sale; modest size but may prompt short‑term price pressure.
What to watch
The CFO's remaining stake remains sizable, and the sale size is modest relative to market cap.
Background
SEC Form 4 filing discloses an insider transaction by Relay Therapeutics' CFO.
Ticker impact
CFO Thomas Catinazzo sold 17,717 shares for $329K via a 10b5‑1 plan, reducing his stake to 105,134 shares.
likely pressure as the market prices in the insider sell
A CFO off‑loading shares, even modestly, often triggers cautious sentiment and modest downside risk.
Market effects
Minimal impact on biotech sector; isolated insider transaction.
No broader regional effect.
Limited to Relay Therapeutics investors.
Counterpoint
The sale could be routine under a pre‑arranged plan and not reflect company fundamentals.
Key entities
- companyRelay Therapeutics, Inc.
Biopharma company developing precision medicines.
- personCatinazzo Thomas
Chief Financial Officer of Relay Therapeutics.